{"entity":{"id":"bayer","kind":"company","name":"Bayer","aka":[],"tldr":"Bayer owns Xofigo, the only approved alpha emitter, and is developing next-generation actinium PSMA agents.","summary":"Bayer, based in Leverkusen and listed as BAYN.DE, owns Xofigo, or radium-223, the only approved alpha emitter, and is developing next-generation actinium-225 PSMA agents. Its oncology portfolio includes 225Ac-PSMA-Trillium, also known as BAY 3563254, darolutamide in prostate cancer, sevabertinib for HER2-mutant non-small-cell lung cancer approved in 2025, larotrectinib, developed earlier with Lilly, and copanlisib, with the AlphaBreak and AcTION actinium trials linked in OnCo. In September 2026 it agreed to sell Stivarga, or regorafenib, to the German company Grünenthal for up to 375 million euros, a sale expected to close by the end of 2026 or early 2027. OnCo also connects it to colorectal, liver, GIST and desmoid tumour pages, to the Norwegian Radium Hospital in Oslo, and to its venture arm Leaps by Bayer. Whether a targeted alpha emitter can go further than radium-223 did is the open question its PSMA programme will answer. Actinium-225 PSMA agents have their own page.","asOf":"2026-10-29","wikipedia":"https://en.wikipedia.org/wiki/Bayer","links":[{"label":"Official website","url":"https://www.bayer.com"},{"label":"Grünenthal acquires Stivarga from Bayer (September 2026)","url":"https://www.grunenthal.com/en/press-room/press-releases/2026/gruenenthal-acquires-cancer-treatment-stivarga"}],"tags":[],"related":[],"cancers":[],"sections":["radiopharma","targeted-therapy"],"technologies":[],"targets":[],"drugs":["ac225-psma"],"companies":["leaps-by-bayer"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06452277","nct05794906","nct07450599","nct04464226","nct06246643","nct06914128","nct06760819","nct05587296","nct02637687","nct07811193"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Checked 29 October 2026: Grünenthal's release of 21 September 2026 announces an agreement with Bayer AG to acquire Stivarga for up to 375 million euros, expected to close by the end of 2026 or early 2027. Bayer's own media pages refused automated reading, so the sale is cited from the buyer. No Bayer acquisition of an oncology company in 2025-2026 was found, though the web search budget ran out before a full sweep."],"hq":"Leverkusen","country":"DE","companyType":"pharma","website":"https://www.bayer.com","ticker":"BAYN.DE","investors":[],"funding":[]},"route":"/companies/bayer/","neighbours":{"section":[{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"ac225-psma","kind":"drug","name":"Actinium-225 PSMA agents","route":"/drugs/ac225-psma/"},{"id":"anetumab-ravtansine","kind":"drug","name":"Anetumab ravtansine","route":"/drugs/anetumab-ravtansine/"},{"id":"copanlisib","kind":"drug","name":"Copanlisib","route":"/drugs/copanlisib/"},{"id":"darolutamide","kind":"drug","name":"Darolutamide","route":"/drugs/darolutamide/"},{"id":"larotrectinib","kind":"drug","name":"Larotrectinib","route":"/drugs/larotrectinib/"},{"id":"radium-223","kind":"drug","name":"Radium-223 dichloride","route":"/drugs/radium-223/"},{"id":"regorafenib","kind":"drug","name":"Regorafenib","route":"/drugs/regorafenib/"},{"id":"sevabertinib","kind":"drug","name":"Sevabertinib","route":"/drugs/sevabertinib/"},{"id":"sorafenib","kind":"drug","name":"Sorafenib","route":"/drugs/sorafenib/"}],"company":[{"id":"leaps-by-bayer","kind":"company","name":"Leaps by Bayer","route":"/companies/leaps-by-bayer/"}],"trial":[{"id":"nct06246643","kind":"trial","name":"A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies","route":"/trials/nct06246643/"},{"id":"nct06914128","kind":"trial","name":"A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors","route":"/trials/nct06914128/"},{"id":"nct05794906","kind":"trial","name":"A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer","route":"/trials/nct05794906/"},{"id":"nct07811193","kind":"trial","name":"A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum","route":"/trials/nct07811193/"},{"id":"nct07450599","kind":"trial","name":"A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have Hi","route":"/trials/nct07450599/"},{"id":"nct05587296","kind":"trial","name":"A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer","route":"/trials/nct05587296/"},{"id":"nct06452277","kind":"trial","name":"A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-sma","route":"/trials/nct06452277/"},{"id":"nct06760819","kind":"trial","name":"A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)","route":"/trials/nct06760819/"},{"id":"nct02637687","kind":"trial","name":"A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children","route":"/trials/nct02637687/"},{"id":"alphabreak","kind":"trial","name":"AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)","route":"/trials/alphabreak/"},{"id":"alsympca","kind":"trial","name":"ALSYMPCA","route":"/trials/alsympca/"},{"id":"anetumab-vs-vinorelbine-mpm","kind":"trial","name":"Anetumab ravtansine versus vinorelbine in relapsed mesothelin-positive pleural mesothelioma","route":"/trials/anetumab-vs-vinorelbine-mpm/"},{"id":"aramis","kind":"trial","name":"ARAMIS","route":"/trials/aramis/"},{"id":"aranote","kind":"trial","name":"ARANOTE","route":"/trials/aranote/"},{"id":"arasens","kind":"trial","name":"ARASENS","route":"/trials/arasens/"},{"id":"concur","kind":"trial","name":"CONCUR","route":"/trials/concur/"},{"id":"correct","kind":"trial","name":"CORRECT","route":"/trials/correct/"},{"id":"decision-sorafenib","kind":"trial","name":"DECISION","route":"/trials/decision-sorafenib/"},{"id":"era-223","kind":"trial","name":"ERA 223","route":"/trials/era-223/"},{"id":"grid","kind":"trial","name":"GRID","route":"/trials/grid/"},{"id":"navigate","kind":"trial","name":"NAVIGATE","route":"/trials/navigate/"},{"id":"peace-3","kind":"trial","name":"PEACE-3 (EORTC 1333)","route":"/trials/peace-3/"},{"id":"regobone","kind":"trial","name":"REGOBONE","route":"/trials/regobone/"},{"id":"nct07071961","kind":"trial","name":"Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Di","route":"/trials/nct07071961/"},{"id":"resorce","kind":"trial","name":"RESORCE","route":"/trials/resorce/"},{"id":"sharp","kind":"trial","name":"SHARP","route":"/trials/sharp/"},{"id":"soho-01","kind":"trial","name":"SOHO-01","route":"/trials/soho-01/"},{"id":"nct04464226","kind":"trial","name":"Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer","route":"/trials/nct04464226/"},{"id":"tapur","kind":"trial","name":"TAPUR (Targeted Agent and Profiling Utilization Registry)","route":"/trials/tapur/"}],"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"desmoid-tumour","kind":"cancer","name":"Desmoid tumour","route":"/cancers/desmoid-tumour/"},{"id":"gist","kind":"cancer","name":"Gastrointestinal stromal tumour (GIST)","route":"/cancers/gist/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"her2-mutant-nsclc","kind":"cancer","name":"HER2-mutant non-small-cell lung cancer","route":"/cancers/her2-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ntrk-fusion-nsclc","kind":"cancer","name":"NTRK fusion-positive non-small-cell lung cancer","route":"/cancers/ntrk-fusion-nsclc/"},{"id":"osteosarcoma","kind":"cancer","name":"Osteosarcoma","route":"/cancers/osteosarcoma/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"salivary-gland","kind":"cancer","name":"Salivary gland cancers","route":"/cancers/salivary-gland/"},{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/"}],"paper":[{"id":"paper-grothey-correct-regorafenib-lancet-2013","kind":"paper","name":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT)","route":"/key-papers/paper-grothey-correct-regorafenib-lancet-2013/"}],"term":[{"id":"nexavar-compulsory-licence","kind":"term","name":"Nexavar compulsory licence (India, 2012)","route":"/terms/nexavar-compulsory-licence/"}],"institution":[{"id":"oslo-radium-hospital","kind":"institution","name":"Oslo University Hospital, The Norwegian Radium Hospital","route":"/institutions/oslo-radium-hospital/"}],"technology":[{"id":"actinium-225-supply","kind":"technology","name":"Actinium-225 supply: thorium stocks, accelerators and radium targets","route":"/technologies/actinium-225-supply/"},{"id":"radiopharmaceutical-gmp-release","kind":"technology","name":"Radiopharmaceutical GMP and releasing a drug that decays","route":"/technologies/radiopharmaceutical-gmp-release/"}]}}